LIFE
LIFE
Sciences
NK LIFE
Gamma LIFE
ALPHA LIFE
AI LIFE
Extending Human Lifespan
by 30 Years
Technology Platform I
In Vivo CAR T/NK engineered with base editing to target CAD,
cellular senescence and tumors
Technology Platform II
Human bioenergy based biophysical and digital therapy
Technology Platform III
Novel LNP/mRNA nanovaccines for CNS and cancer
Pipeline
Anti-Aging
LIFE Sciences Corp is determined to extend human lifespan by 30 years through three subsidiary companies with three distinct innovative platforms:
-
Precision immunotherapy with "Off the Shelf" CAR T/NK/M cells. (NK LIFE)
-
Anti-aging intranasal nanovaccine and nanomedicine for Alzheimer's & Parkinson's. (ALPHA LIFE)
-
Human bioenergy based digital therapy for Parkinson's Disease. (GAMMA LIFE)
In cardiology, we also utilize in vivo CAR Treg to induce tolerance to atherosclerosis in CAD and immuno-senolytic CAR T/NK targeting cellular senescence (aging cells) for the treatment of cardiomyopathy.
Immunotherapy for blood Tumor
Immunotherapy for solid Tumor
MKure for the treatment of BCMA exposed/relapsed MM is a CAR-NK therapy which contains a proprietary GPRC5D nanobody derived from llama. Scored 19 by the NIH SBIR Phase I Program, MKure is currently in animal studies, NKLife plans for an IIT Phase I trial in 2026. MKure has a strong IP portfolio which consists of the GPRC5D nanobody, the genetically designed CAR sequence, and the proprietary technology involved in bioprocessing NK cells from healthy donors. In addition, NKLIFE is pioneering in vivo CAR-T technology through LNP-mRNA platform targeting T cells in situ.
First in its class, DKURE is a Dendritic Cells (DC) targeted LNP formulation that can deliver mRNA encoding tumor antigen directly to the lymph nodes to generate anti-tumor T cell responses. In vivo animal data demonstrated high anti-tumor potency (Abstract in 2025 ASCO). DKure encoding GPRC3 is entering IIT Phase I trial in 2026 for the treatment of late stage HCC.
L-KURE is an in vivo CAR-T with a llama derived nanobody against DLL3 for the treatment of lung cancer.
G-KURE is an in vivo CAR-T with a llama derived nanobody raised against Claudin6 for the treatment of gastric cancer.
A Fortune 500 Management
Team
Formed in November 2021 by five scientists with Merck, J&J, Abbvie, Rockefeller and Sloan Kettering backgrounds
Lei Zhong, PhD. Chairman and CEO
Pace Yang, PhD. COO/CFO
Charlie Gong, PhD. CTO
Victor Jin, PhD. CSO (Interim)
Feng Zhu, MD. PhD. CMO
Bo Huang, PhD. Chief Scientific Advisor
Yi Lin, MD. PhD. Chief Medical Advisor
William Johnson, PhD. Corporate Affairs
Samuel Khatami, PhD. CDO
Call us a little crazy, but we have ways to add 30yrs of healthy life to all
Milestones
Scroll to learn about our company’s journey
LIFE
